Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pretargeting: taking an alternate route for localizing radionuclides.

Sharkey RM, Chang CH, Rossi EA, McBride WJ, Goldenberg DM.

Tumour Biol. 2012 Jun;33(3):591-600. doi: 10.1007/s13277-012-0367-6. Epub 2012 Mar 7. Review.

PMID:
22396041
2.

Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.

Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, Yeldell D, Griffiths GL, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3897S-913S.

3.

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.

Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM.

Bioconjug Chem. 2002 Sep-Oct;13(5):1054-70.

PMID:
12236788
4.

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM.

Semin Nucl Med. 2010 May;40(3):190-203. doi: 10.1053/j.semnuclmed.2009.12.002. Review.

5.

A universal pretargeting system for cancer detection and therapy using bispecific antibody.

Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM.

Cancer Res. 2003 Jan 15;63(2):354-63.

6.

Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.

Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, Goldenberg DM.

Bioconjug Chem. 2000 Nov-Dec;11(6):842-54.

PMID:
11087333
7.

Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.

van Schaijk FG, Oosterwijk E, Soede AC, Oyen WJ, McBride WJ, Griffiths GL, Goldenberg DM, Corstens FH, Boerman OC.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3880S-5S.

8.

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.

Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7109s-7121s.

9.

Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.

McBride WJ, Zanzonico P, Sharkey RM, Norén C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM.

J Nucl Med. 2006 Oct;47(10):1678-88.

10.

Tumor pretargeting for radioimmunodetection and radioimmunotherapy.

Zhu H, Jain RK, Baxter LT.

J Nucl Med. 1998 Jan;39(1):65-76.

11.

Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.

van Schaijk FG, Boerman OC, Soede AC, McBride WJ, Goldenberg DM, Corstens FH, Oosterwijk E.

Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1089-95. Epub 2005 May 18.

PMID:
15902440
12.

A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.

Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM.

Cancer Res. 2008 Jun 15;68(12):4819-26. doi: 10.1158/0008-5472.CAN-08-0232.

13.

Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.

Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Tekabe Y, Khaw BA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):824-39. doi: 10.1007/s00259-011-2050-3.

PMID:
22302089
14.

Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.

van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7130s-7136s.

15.

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.

Sharkey RM, Karacay H, Griffiths GL, Behr TM, Blumenthal RD, Mattes MJ, Hansen HJ, Goldenberg DM.

Bioconjug Chem. 1997 Jul-Aug;8(4):595-604.

PMID:
9258460
16.
17.

Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.

Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J.

J Nucl Med. 1998 Nov;39(11):1937-43.

18.

Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.

Boerman OC, Kranenborg MH, Oosterwijk E, Griffiths GL, McBride WJ, Oyen WJ, de Weijert M, Oosterwijk-Wakka J, Hansen HJ, Corstens FH.

Cancer Res. 1999 Sep 1;59(17):4400-5.

19.

Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.

van de Watering FC, Rijpkema M, Robillard M, Oyen WJ, Boerman OC.

Front Med (Lausanne). 2014 Nov 18;1:44. doi: 10.3389/fmed.2014.00044. eCollection 2014. Review.

20.

Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.

Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM.

Leukemia. 2005 Jun;19(6):1064-9.

PMID:
15815716

Supplemental Content

Support Center